ReNeuron has announced its 3rd exosome collaboration agreement and has made another step to justifying the strategic shift to exosomes as announced earlier this month. As a reminder ReNeuron’s exosomes are derived from human neural stem cells, and are clinical-grade, scalable and have a natural ability to cross the blood-brain barrier. Exosomes can be used to deliver therapeutics for diseases of the brain. The agreement today is with an undisclosed major US pharmaceutical company, but like the p ....
25 Jun 2020
Exosomes gaining traction – 3rd pharma collaboration announced
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Exosomes gaining traction – 3rd pharma collaboration announced
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
25 Jun 2020 -
Author:
Edward Thomason -
Pages:
3
ReNeuron has announced its 3rd exosome collaboration agreement and has made another step to justifying the strategic shift to exosomes as announced earlier this month. As a reminder ReNeuron’s exosomes are derived from human neural stem cells, and are clinical-grade, scalable and have a natural ability to cross the blood-brain barrier. Exosomes can be used to deliver therapeutics for diseases of the brain. The agreement today is with an undisclosed major US pharmaceutical company, but like the p ....